Since its emergence in China at the end of 2019, SARS-CoV-2 has rapidly spread across the world to become a global public health emergency. Since then, the pandemic has evolved with the large worldwide emergence of new variants, such as the Alpha (B.1.1.7 variant), Beta (B.1.351 variant), and Gamma (P.1 variant), and some other under investigation such as the A.27 in France. Many studies are focusing on antibody neutralisation changes according to the spike mutations, but to date, little is known regarding their respective replication capacities. In this work, we demonstrate that the Alpha variant provides an earlier replication , on Vero E6 and A549 cells, than Beta, Gamma, A.27, and historical lineages. This earlier replication was associated with higher infectious titres in cell-culture supernatants, in line with the higher viral loads observed among Alpha-infected patients. Interestingly, Beta and Gamma variants presented similar kinetic and viral load than the other non-Alpha-tested variants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716835 | PMC |
| http://dx.doi.org/10.3389/fcimb.2021.792202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Calcitriol Treated Mesenchymal Stem Cells Modulated Immune Response in Collagen-Induced Rheumatoid Arthritis in BALB/c Mice.
Transplant Proc
January 2025
School of Medical Sciences, Emam Reza Hospital Sirjan Faculty of Medical Sciences, Sirjan, Iran.
Background And Aim: Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily involves synovial joints. During the past decade, disease-modifying antirheumatic drugs and biologic agents have been introduced for the treatment of RA. However, they have limitations, including incomplete treatment response, adverse effects requiring drug withdrawal, fall off in efficacy over time, high cost of biologic agents, and refractory cases.
View Article and Find Full Text PDFWBP1L, a transmembrane adaptor protein involved in the regulation of hematopoiesis, is controlled by CRL1 ubiquitin ligases.
Biochem Biophys Res Commun
January 2025
Laboratory of Leukocyte Signalling. Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 14220, Prague, Czech Republic. Electronic address:
WBP1L is a broadly expressed transmembrane adaptor protein involved in regulating hematopoietic stem cell function and T cell development. It interacts with NEDD4-family E3 ubiquitin ligases and regulates important chemokine receptor CXCR4. Using tandem affinity purification coupled with mass spectrometry, we identified novel WBP1L interactions with the IFNγ receptor and the Cullin-RING ubiquitin ligases CRL1.
View Article and Find Full Text PDFA longitudinal study on the detection of anti-Leishmania antibodies in a captive European mink (Mustela lutreola) population and their correlation with serum protein electrophoresis.
Res Vet Sci
January 2025
Animal Pathology Department, Veterinary Faculty, University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain; Clinical Immunology Laboratory, Veterinary Faculty, University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain. Electronic address:
Leishmaniosis, caused by Leishmania infantum and transmitted by sand flies, is a significant zoonotic disease. Dogs are primary reservoirs, but other domestic animals, such as cats and ferrets, and wild species, including Eurasian otters and European mink, can be hosts. This study focused on European mink, a critically endangered species, investigating the seroprevalence of L.
View Article and Find Full Text PDFSafety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.
Hum Vaccin Immunother
December 2025
Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).
View Article and Find Full Text PDFA Three-agent Regimen for Triple Negative Breast Cancer Treatment.
Recent Pat Anticancer Drug Discov
January 2025
Department of Medical Oncology, Affiliated Hospital of Inner Mongolia Medical University, NO1 Tongdao Northern Road, Hohhot, 010050, China.
Background: Triple-negative breast cancer (TNBC) has a poor prognosis with current treatment options. Novel therapeutic strategies are urgently needed to enhance treatment outcomes for TNBC.
Objective: This study evaluated the efficacy of a three-agent regimen compared to existing treatment regimens in a TNBC mouse model, and elucidated its potential mechanisms of action.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!